Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation.
about
Immune Cells and Inflammation in Diabetic NephropathyPalmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic RetinopathyRole of enteric neurotransmission in host defense and protection of the gastrointestinal tractAdipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota.The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.Enteric glial cells and their role in the intestinal epithelial barrierPalmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels.Modulation of lipopolysaccharide-induced neuronal response by activation of the enteric nervous system.Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent.The second brain in autism spectrum disorder: could connexin 43 expressed in enteric glial cells play a role?Endocannabinoids--at the crossroads between the gut microbiota and host metabolism.Palmitoylethanolamide Modulates Inflammation-Associated Vascular Endothelial Growth Factor (VEGF) Signaling via the Akt/mTOR Pathway in a Selective Peroxisome Proliferator-Activated Receptor Alpha (PPAR-α)-Dependent Manner.Enteric Glial Cells: A New Frontier in Neurogastroenterology and Clinical Target for Inflammatory Bowel Diseases.Homeostatic PPARα Signaling Limits Inflammatory Responses to Commensal Microbiota in the Intestine.Analysis of Important Gene Ontology Terms and Biological Pathways Related to Pancreatic Cancer.Endocannabinoids, related compounds and their metabolic routes.Emerging roles for enteric glia in gastrointestinal disordersThe enteric glia: identity and functions.N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.The anti-inflammatory compound palmitoylethanolamide inhibits prostaglandin and hydroxyeicosatetraenoic acid production by a macrophage cell lineEnteric glia regulate gut motility in health and disease.Cannabinoid Receptors in Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance.Palmitoylethanolamide Exerts Antiproliferative Effect and Downregulates VEGF Signaling in Caco-2 Human Colon Carcinoma Cell Line Through a Selective PPAR-α-Dependent Inhibition of Akt/mTOR Pathway.An update on PPAR activation by cannabinoids.The Role of the Endocannabinoid System in the Brain-Gut Axis.Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease.Potential roles of enteric glia in bridging neuroimmune communication in the gut.HIV-1 Tat-induced diarrhea evokes an enteric glia-dependent neuroinflammatory response in the central nervous system.IL-1β-Induced Downregulation of the Multifunctional PDZ Adaptor PDZK1 Is Attenuated by ERK Inhibition, RXRα, or PPARα Stimulation in Enterocytes.Molecular Signaling and Dysfunction of the Human Reactive Enteric Glial Cell Phenotype: Implications for GI Infection, IBD, POI, Neurological, Motility, and GI DisordersTLR2 and TLR9 modulate enteric nervous system inflammatory responses to lipopolysaccharide.Multiple Gene-Environment Interactions on the Angiogenesis Gene-Pathway Impact Rectal Cancer Risk and Survival.Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse.Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.Endocannabinoid-related compounds in gastrointestinal diseases.Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome.Toll-like Receptors and Inflammatory Bowel Disease.Existing and emerging therapies for managing constipation and diarrhea.HIV-1 Tat-induced diarrhea is improved by the PPARalpha agonist, palmitoylethanolamide, by suppressing the activation of enteric glia.
P2860
Q26772998-7467090D-AE38-4B47-9CA6-D1534752B5F3Q26776171-6B9727AF-8549-4A56-88A7-DF9D958313ADQ26827692-1A9952A0-561B-4602-938C-3A6FDB1F0528Q30372594-CEE78512-C539-4889-9A69-9C8D23B787C0Q31122398-EFA29766-DF07-47B6-850E-08BB316B5130Q34093834-3CCC5CC9-22A0-4CBB-815D-424468B306ECQ34571380-0BCF69C9-5D06-42CF-9AF8-19C2AA1AB2B2Q34789106-4DDEAEDB-2EDF-49CE-AB78-9B21065DD119Q34795735-BD0AEF85-EFA1-4E1F-9617-1F0A51889218Q35813000-96CF3F27-0528-4315-B03C-4B1DD6E4E156Q35871872-4773C5DB-B511-44E3-B418-B51E181C5163Q36027964-F360FAB4-A6A5-4B7E-8F00-8C77A255C30AQ36477852-70C7B1EB-89D2-4761-B1DC-B74A89782F23Q36923759-31CD291C-876C-4441-9F5A-E04FFCFB2BA1Q37430812-E2EDD115-F04F-4617-A665-B5238DB2F60BQ38262964-851CF43B-0772-42F2-B925-6D6A57BE7382Q38358488-17AA601D-5903-4C57-AF4B-D5381F936A22Q38363866-CAF72A3B-C2DE-44E7-B1FC-D4519481A655Q38599291-5CBE5471-AD28-4B17-8A84-0D8162E007E8Q38709659-DC526F0F-5F62-4F79-950B-733C7D86367BQ38736939-D79495FE-E803-4BD6-AF93-B619A4EB955EQ38761437-9547CF92-6477-4387-91E1-08D3F5C74EB3Q38789993-9534854C-823C-4C2E-9421-935B10583B5BQ38808034-714A91FB-7DE7-4A8C-BFE7-8A77405D42C8Q38822341-80B4F756-2E3A-4678-9306-46E10597A038Q38918638-46A3A475-AC3D-4D0C-A08F-F2F92876DF05Q38937293-C844D36F-54C6-4469-9303-55118E3E0A6FQ39049151-4E8C4128-F2E7-46CB-B87B-9F0D48FDA832Q40086501-3A4EAF15-53D1-42D0-8314-1D247BDD2109Q40322820-B4D1045E-0A2F-4D23-B048-047B82336C4FQ40613666-9D4EBA2D-D369-49BD-99D7-B2952C29A33DQ41562731-1A305AF5-4435-44F6-A7D8-49BF43F17ACBQ46365529-4DF170F9-5306-4B0C-9C7A-91D8D5D80034Q47222146-B4883634-82EC-4A0E-B8CA-4D25B460B7C3Q47818880-2E3CD72C-5646-4D82-8242-BCB6ED941BE5Q47839554-E32EAFE0-1DE1-46B9-8279-017EBA302029Q48274669-D0D17720-49CE-49B8-8785-F183F8E1F678Q49416505-BDC1D55A-2F55-4CA6-A9AB-85AE76C5B864Q49677641-CD73677F-5898-4CBE-BC52-8801F0B48D10Q51735536-6277D6F2-AA51-4434-81BE-A86217374D0B
P2860
Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Palmitoylethanolamide improves ...... 4-dependent PPAR-α activation.
@en
Palmitoylethanolamide improves ...... 4-dependent PPAR-α activation.
@nl
type
label
Palmitoylethanolamide improves ...... 4-dependent PPAR-α activation.
@en
Palmitoylethanolamide improves ...... 4-dependent PPAR-α activation.
@nl
prefLabel
Palmitoylethanolamide improves ...... 4-dependent PPAR-α activation.
@en
Palmitoylethanolamide improves ...... 4-dependent PPAR-α activation.
@nl
P2093
P50
P921
P1433
P1476
Palmitoylethanolamide improves ...... 4-dependent PPAR-α activation.
@en
P2093
Elena Capoccia
Fabio Turco
Ilaria Palumbo
P304
P356
10.1136/GUTJNL-2013-305005
P407
P577
2013-09-30T00:00:00Z